Repligen Co. (NASDAQ:RGEN) Shares Acquired by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD lifted its stake in Repligen Co. (NASDAQ:RGEN) by 11.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,136,054 shares of the biotechnology company’s stock after purchasing an additional 743,815 shares during the period. Price T Rowe Associates Inc. MD owned about 12.74% of Repligen worth $1,027,165,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock valued at $734,251,000 after purchasing an additional 56,723 shares in the last quarter. Champlain Investment Partners LLC raised its stake in Repligen by 8.6% in the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company’s stock valued at $222,176,000 after buying an additional 122,595 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Repligen by 23.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock worth $145,508,000 after acquiring an additional 191,439 shares in the last quarter. Conestoga Capital Advisors LLC increased its holdings in shares of Repligen by 0.7% in the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock valued at $136,395,000 after acquiring an additional 6,872 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in shares of Repligen by 2.5% during the 4th quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company’s stock worth $83,693,000 after acquiring an additional 14,398 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on the stock. JPMorgan Chase & Co. increased their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. StockNews.com cut shares of Repligen from a “hold” rating to a “sell” rating in a research report on Thursday, April 17th. Royal Bank of Canada raised their price objective on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a report on Friday, February 21st. Finally, TD Cowen began coverage on Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 target price for the company. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Repligen currently has a consensus rating of “Hold” and an average price target of $176.82.

Insider Buying and Selling

In other Repligen news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. The trade was a 31.53 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Repligen Trading Up 1.9 %

Shares of RGEN stock opened at $141.53 on Thursday. The company has a market capitalization of $7.95 billion, a P/E ratio of -277.50, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The business’s 50 day moving average is $139.84 and its two-hundred day moving average is $145.67. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Equities analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.